MIDD and FDA:
What Biotechs need to know about ICH M15
Model-Informed Drug Development (MIDD) has become a critical driver of both regulatory success and asset valuation for small and mid-sized biotech companies. By integrating nonclinical, clinical, and prior knowledge through modeling and simulation, MIDD enables data-driven decision-making across the entire drug development lifecycle. The ICH M15 guidance introduces a harmonized framework that allows these models to be formally recognized as “MIDD evidence” by regulatory authorities such as the FDA.
A lifecycle strategy for risk reduction
MIDD supports development from early translational modeling and First-in-Human dose prediction to dose optimization and exposure-response analysis in later phases. It also enables simulation of complex scenarios, including special populations and drug-drug interactions, ultimately strengthening regulatory submissions.
A new standard for evidence assessment
ICH M15 establishes a structured evaluation framework based on:
- Clear definition of the regulatory question and context of use
- Assessment of model risk (impact of decisions and consequences of error)
- Evaluation of model influence on regulatory decisions
Higher-risk models require more rigorous validation and performance standards.
Operational Rigor: MAP and MAR
Two key documentation elements are now essential:
- Model Analysis Plan (MAP): predefined objectives, methods, and success criteria
- Model Analysis Report (MAR): comprehensive documentation of model performance, assumptions, and limitations
This ensures transparency, reproducibility, and regulatory readiness.
Early FDA alignment as a strategic lever
Early engagement with the FDA; particularly through MIDD-focused meetings, is critical. Presenting a well-defined MAP and model strategy can secure early agreement, reduce regulatory risk, and enhance investor confidence.
ICH M15 marks a shift toward a “Model-First” paradigm. For biotech companies, adopting MIDD is no longer optional; it is a strategic necessity to accelerate development, optimize investment, and achieve successful regulatory outcomes.
